GleamWall
中文EN

LIPO LIPELLA PHARMACEUTICALS INC.

Pharmaceutical Preparations · OTC · SEC CIK 1347242 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.4%
TTM net income YoY-25.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,387.9%
Net margin-1,367.4%
FCF margin—
EBITDA margin-1,387.2%

Returns

ROE-361.8%
ROA-236.4%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets36.7%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-24.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-31
Income statement
Revenue$0$86,727$129,390$173,666$80,380$136,431$145,880$120,842
R&D expense$720,973$791,581$993,475$1.06M$1.05M$661,558$842,600$454,200
SG&A expense$553,299$651,721$463,736$562,622$493,102$427,062$520,926$396,236
Operating income-$1.27M-$1.36M-$1.33M-$1.45M-$1.46M-$952,189-$1.22M-$729,594
Interest expense———————$0
Pretax income-$1.25M-$1.33M-$1.31M-$1.44M-$1.44M-$938,146-$1.19M-$688,884
Net income-$1.25M-$1.33M-$1.31M-$1.44M-$1.44M-$938,146-$1.19M-$688,884
EBITDA-$1.27M-$1.36M-$1.33M-$1.45M-$1.46M-$950,818-$1.22M-$728,871
EPS (basic)-0.28-0.31-0.64—-1.29-0.99-1.31—
EPS (diluted)-0.28-0.31-0.64—-1.29-0.99-1.31—
Weighted avg. shares (diluted)4.55M4.31M2.06M—1.12M950,669911,515—
Balance sheet
Cash & equivalents$1.86M$2.78M$4.23M$2.18M$1.35M$1.19M$2.11M$3.29M
Receivables———$84,713$31,079$35,332$68,934$32,286
Current assets$2.08M$3.44M$4.82M$2.62M$2.08M$2.08M$3.01M$3.43M
PP&E, net$7,699$8,420$9,142$9,864$10,585$11,307$12,029$12,750
Total assets$2.35M$3.72M$4.86M$2.67M$2.16M$2.18M$3.14M$3.58M
Current liabilities$642,399$746,898$776,846$754,417$701,186$480,313$551,881$385,355
Total liabilities$862,215$978,534$776,847$754,417$701,186$480,313$575,878$432,726
Shareholders' equity$1.49M$2.74M$4.08M$1.92M$1.46M$1.70M$2.56M$3.14M
Shares outstanding4.62M4.47M2.55M1.21M1.09M7.61M7.04M756,743
Cash flow statement
Operating cash flow-$926,057-$1.43M-$1.43M-$990,413-$653,103-$918,792-$1.39M-$727,710
Capital expenditure———————$0
Free cash flow———————-$727,710
Investing cash flow———————$0
Financing cash flow$0-$10,047$3.47M$1.82M$820,332$0$200,000$1.61M
Depreciation & amortization$722$721$722$721$722$1,371$721$723

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.